Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sareum, a Cambridge-headquartered cancer drug discovery company, has reported positive results from a pre-clinical in-vivo efficacy studies of their Chk1 (Checkpoint Kinase 1) cancer research programme.
Subscribe to our email newsletter
The Chk1 programme is a research collaboration between Sareum and the Institute of Cancer Research and Cancer Research Technology aimed at assessing how best to harness Chk1 to create cancer therapeutics.
Chk1 plays an important role in controlling a cancer cell’s response to DNA damage, which may be a consequence of the cancer itself, or intentionally caused by chemotherapy or radiotherapy.
During the efficacy studies, a colon cancer pre-clinical model study showed that the combination of Chk1 inhibitor (orally) with a chemotherapeutic, gemcitabine reduced cancer growth rate two-fold compared to treatment with the same dose of gemcitabine without the Chk1 inhibitor.
The Chk1 inhibitor, when dosed alone, was found to reduce cancer growth in models of AML (acute myeloid leukaemia) and neuroblastoma (a childhood cancer).
Sareum CEO Tim Mitchell said that these results would significantly enhance the licencing package, and assist in selecting the best compound for development into a clinical trials candidate.